|
- Sacituzumab govitecan - Wikipedia
Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate, meaning that the drug targets the Trop-2 receptor that helps the cancer grow, divide and spread, and is linked to topoisomerase inhibitor, which is a chemical compound that is toxic to cancer cells [11]
- 戈沙妥珠单抗（Sacituzumab）：开启肿瘤精准治疗新时代 - 知乎
在肿瘤治疗领域，抗体偶联药物（ADC）正逐渐成为研究热点，而戈沙妥珠单抗（Sacituzumab）更是其中的佼佼者。
- For adult patients | TRODELVY® (sacituzumab govitecan-hziy)
Discover TRODELVY® (sacituzumab govitecan‐hziy) for treatment guidance, clinical trial results, addressing side effects, and patient support services See Important Facts Important Warning
- 注射用芦康沙妥珠单抗说明书
注射用芦康沙妥珠单抗说明书 请仔细阅读说明书并在医师或药师指导下使用 【药品名称】 通用名称:注射用芦康沙妥珠单抗商品名称:佳泰莱英文名称:Sacituzumab Tirumotecan for Injection汉语拼音:Zhusheyong Lukangshatuozhu Dankang
- Sacituzumab govitecan - Drugs. com
Sacituzumab govitecan is a targeted antibody-drug conjugate (ADC) designed to deliver anticancer medicine directly into cells with Trop-2 proteins Research has found that certain types of cancer cells contain more Trop-2 protein than noncancerous cells
- 戈沙妥组单抗 (Sacituzumab govitecan-hziy) - 药物靶点：Top I x Trop-2_在研适应症：转移性三阴性 . . .
Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug called govitecan Sacituzumab attaches to TROP2 positive tumor cells in a targeted way and delivers govitecan to kill them
- 認識化療藥品Sacituzumab govitecan | 衛教單張 - 中國醫藥大學附設醫院
Sacituzumab govitecan是結合單株抗體與小分子細胞毒性藥物而成的抗體藥物複合體，具有專一殺死腫瘤細胞的作用。
- Sacituzumab Govitecan-hziy - NCI - National Cancer Institute
Sacituzumab govitecan-hziy is a type of targeted therapy drug called an antibody-drug conjugate It consists of a monoclonal antibody linked to a toxic drug called SN-38 that binds to a protein on the surface of some cancer cells
|
|
|